Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--( BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update.
“We made significant progress across our oncology pipeline in recent months,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA. Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end. We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH in December.”
Pipeline Highlights
Varegacestat:
IM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, and Immunome expects to present an updated dataset at the 2026 American Society of Hematology (ASH) Annual Meeting on December 14, 2026. Previously reported results as of the June 26, 2026 abstract data cutoff included:
IM-1617: In June 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-1617 in patients with advanced solid tumors. IM-1617 is an ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload. The study is expected to include participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer and breast cancer.
IM-1340: Immunome received IND clearance for IM-1340 in September 2026. The company plans to initiate a Phase 1 trial by year-end. IM-1340 is a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload. The trial is expected to include patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, small cell lung cancer and neuroendocrine neoplasms.
IM-3050: In July 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-3050 in patients with FAP-expressing advanced solid tumors. The trial is designed to evaluate safety, tolerability, dosimetry, pharmacokinetics and preliminary anti-tumor activity of the investigational FAP-targeted radioligand therapy.
Preclinical ADC Pipeline: Immunome expects to submit an IND for IM-1335 in late 2026. The program is directed at an undisclosed solid tumor target and incorporates HC74. Additional undisclosed ADCs are in discovery and lead optimization to support INDs in 2027 and beyond.
Third Quarter 2026 Financial Results
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA and an MAA has been validated by the EMA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radioligand therapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “planned,” “expected,” “focused,” “advance,” “projected,” “will,” “potential,” “expect,” “intend,” “plan,” “pursue,” “support,” “expects,” “advancing,” and similar expressions to identify these forward-looking statements. These forward-looking statements include statements regarding progress of Immunome’s pipeline and achievement of key milestones; the proposed timeline for expected data with respect to Immunome’s pipeline; Immunome’s plans and timing for submission of additional INDs; the design and anticipated scope of Immunome’s ongoing and planned clinical trials; the potential of Immunome’s pipeline of assets to be first-in-class and best-in-class; Immunome’s plans and timeline for initiating additional clinical trials; Immunome’s expected cash runway; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that preclinical data may not be predictive of clinical data or that early clinical data may not be predictive of later clinical data, regulatory approval or commercial viability; the risk of reliance on third-party vendors; the risk that Immunome’s programs and product candidates fail to achieve their intended endpoints; the risk that Immunome will not be able to realize the benefits of its strategic transactions; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; Immunome’s ability to grow and advance its pipeline and successfully execute on its business plan; and other risks and uncertainties included under the caption “Risk Factors” in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 11, 2026, and in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to be filed with the SEC later today. These documents can also be accessed on Immunome’s website at www.immunome.com by clicking on the link “Financials” under the “Investors” tab. The forward-looking statements included in this press release are made only as of the date hereof. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
IMMUNOME, INC.
Condensed Consolidated Balance Sheets
(in thousands)
September 30, 2026
December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents
$
212,842
$
653,482
Marketable securities
248,740
—
Prepaid expenses and other current assets
16,213
7,295
Total current assets
477,795
660,777
Property and equipment, net
16,670
14,636
Operating right-of-use assets
3,881
2,978
Restricted cash
210
210
Other long-term assets
6,971
4,587
Total assets
$
505,527
$
683,188
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
4,461
$
3,339
Accrued expenses and other current liabilities
36,505
41,651
Total current liabilities
40,966
44,990
Operating lease liabilities, net of current portion
10,258
3,855
Total liabilities
51,224
48,845
Stockholders’ equity:
Preferred stock
—
—
Common stock
11
11
Additional paid-in capital
1,395,672
1,362,496
Accumulated other comprehensive loss
(467
)
—
Accumulated deficit
(940,913
)
(728,164
)
Total stockholders’ equity
454,303
634,343
Total liabilities and stockholders’ equity
$
505,527
$
683,188
IMMUNOME, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
Three Months Ended September 30,
2026
2025
Collaboration revenue
$
—
$
—
Operating expenses:
Research and development (1)
69,506
49,193
General and administrative (1)
20,856
10,945
Total operating expenses
90,362
60,138
Loss from operations
(90,362
)
(60,138
)
Interest income
4,579
2,681
Net loss
$
(85,783
)
$
(57,457
)
Net loss per share, basic and diluted
$
(0.76
)
$
(0.65
)
Weighted-average shares outstanding, basic and diluted
113,564,748
87,957,868
Comprehensive loss:
Net loss
$
(85,783
)
$
(57,457
)
Unrealized (loss) gain on marketable securities
(134
)
24
Comprehensive loss
$
(85,917
)
$
(57,433
)
(1) Amounts include non-cash share-based compensation as follows (in thousands):
Three Months Ended September 30,
2026
2025
Research and development
$
6,583
$
2,851
General and administrative
6,178
3,896
Total share-based compensation expense
$
12,761
$
6,747